Pharmacokinetic and bioequivalence study of an oral 8 mg dose of rosiglitazone tablets in thai healthy volunteers

Journal of the Medical Association of Thailand

Volumn 93, Issue 6, 2010, Pages 722-728

  Wittayalertpanya, Supeecha ^a   Chompootaweep, Sumana ^a   Thaworn, Nongnuch ^a   Khemsri, Wandee ^a   Intanil, Nuntana ^a  

^a CHULALONGKORN UNIVERSITY   (Thailand)

Author keywords

Bioequivalence; Pharmacokinetic; Rosiglitazone

Indexed keywords

ROSIGLITAZONE; ROSITA; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG HALF LIFE; FLUORESCENCE ANALYSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; REFERENCE VALUE; SINGLE DRUG DOSE; THAILAND; VOLUNTEER;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; AREA UNDER CURVE; ASIAN CONTINENTAL ANCESTRY GROUP; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FLUORESCENCE; HALF-LIFE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; TABLETS; THAILAND; THERAPEUTIC EQUIVALENCY; THIAZOLIDINEDIONES; TIME FACTORS; YOUNG ADULT;

EID: 77954480058     PISSN: 01252208     EISSN: 01252208     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Wagstaff AJ, Goa KL. Rosiglitazone: a review of its use in the management of type 2 diabetes mellitus. Drugs 2002; 62: 1805-37.
2. Cox PJ, Ryan DA, Hollis FJ, Harris AM, Miller AK, Vousden M, et al. Absorption, disposition, and metabolism of rosiglitazone, a potent thiazolidinedione insulin sensitizer, in humans. Drug Metab Dispos 2000; 28: 772-80.
3. Aramwit P, Supasyndh O, Sriboonruang T. Pharmacokinetics of single-dose rosiglitazone in chronic ambulatory peritoneal dialysis patients. J Clin Pharm Ther 2008; 33: 685-90.
4. Wellington K. Rosiglitazone/Metformin. Drugs 2005; 65: 1581-92.
5. Park JY, Kim KA, Kang MH, Kim SL, Shin JG. Effect of rifampin on the pharmacokinetics of rosiglitazone in healthy subjects. Clin Pharmacol Ther 2004; 75: 157-62.
6. Thompson-Culkin K, Zussman B, Miller AK, Freed MI. Pharmacokinetics of rosiglitazone in patients with end-stage renal disease. J Int Med Res 2002; 30: 391-9.
7. Malinowski JM, Bolesta S. Rosiglitazone in the treatment of type 2 diabetes mellitus: a critical review. Clin Ther 2000; 22: 1151-68.
8. Hruska MW, Frye RF. Simplified method for determination of rosiglitazone in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2004; 803: 317-20.
9. Kolte BL, Raut BB, Deo AA, Bagool MA, Shinde DB. Liquid chromatographic method for the determination of rosiglitazone in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2003; 788: 37-44.
10. U.S. Department of Health and Human Services, FDA. Guidance for industry: bioanalytical method validation. Rockville, MD: U.S. Department of Health and Human Services, FDA, CDER, CVM; 2001.
11. Yusuf A, Al Gaai E, Hammami MM. Bioequivalence evaluation of two rosiglitazone tablet formulations. Arzneimittelforschung 2006; 56: 740-3.
12. Thompson-Culkin K, Zussman B, Miller AK, Freed MI. Pharmacokinetics of rosiglitazone in patients with end-stage renal disease. J Int Med Res 2002; 30: 391-9.